Other
Uterine Bleeding
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Uterine Bleeding is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
7
clinical trials
Completed6 · 86%
Unknown status1 · 14%
Clinical Trials
Trial Activity
7 trials
Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding
Completed·—·N/A·NCT04710017·110 enrolled
Chinese Medicine Periodic Therapy for Dysfunctional Uterine Bleeding During Adolescence With Yin Deficiency and Blood Heat Syndrome
Completed·—·Phase 2·NCT04528108·160 enrolled
Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial
Completed·—·N/A·NCT00350480·240 enrolled
The Effect of Ibuprofen on Intrauterine Contraceptive Device Associated Uterine Bleeding
Completed·—·Phase 2·NCT02580344·128 enrolled
The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users
Unknown status·—·Phase 1/2·NCT03264781·44 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)